جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

51 مُخرَج نتائج البحث عن «Kinetics»

مقالوصول مفتوح20262استشهاد· Semantic Scholar

Coumarin-based dual kinase inhibitors targeting CDK6 and VEGFR-2: experimental and computational validation

RSC Advances · مجلد 16 (40) · 46094-46114

ADMET analysis predicted favorable pharmacokinetic and safety profiles. Collectively, these findings identified compound 7e as a promising dual VEGFR-2/CDK6 inhibitor with potent and selective anticancer activity, warranting further preclinical investigation.

coumarinsdual kinase inhibitorsCDK6VEGFR2
مقالوصول مفتوح20261استشهاد· Semantic Scholar

Anti-HCV NS2-3 potential of selected plant bioactive compounds revealed by docking, simulation and DFT

Scientific Reports · مجلد 16 (1)

Presently, there is no vaccine for hepatitis C virus (HCV) and available drugs present with adverse effects that have prompted the search for newer and safer alternatives. The present study evaluated the anti-HCV potential of selected bioactive compounds from Jatropha tanjorensis and Solanum nigrum against HCV non-structural (NS2-3) protein. The selected bioactive compounds (3-methoxy-4-methylaniline, 2,2'-Azoxybis[3-methylpyridine], isopropyl thiophosphondiamide, and squalene) were screened for compliance with Lipinski's role five (LRF) and toxicity using the MCULE tool. Furthermore, the ligands were docked against the NS2-3 (2hd0) protein with ledipasvir, and a co-crystal as controls using the Autodock Vina tool. Docking scores were generated using the London dG scoring function. Following docking, a 200 nanosecond (nsec) simulation run was performed using the Schrodinger Desmond module. In addition, density functional theory (DFT) was utilised to evaluate their reactivities. The selected compounds were not toxic and obeyed the LRF. Molecular docking scores for ledipasvir and the co-crystal were - 8.8 and - 6.3 kcal/mol, respectively while of the ligands ranged from - 3.5 to -7.3 kcal/mol, implying favourable bindings. The amino acid residues involved in the binding were those within the active site of the target protein. RMSD values indicated that isopropyl thiophosphondiamide was the most stable ligand. PSA, MolSA and SASA values suggest stability and availability for water contact. DFT calculations indicate that the compounds were moderately stable and highly reactive, with energy gaps that ranged from 0.5810 to 1.0621 eV. The favourable pharmacokinetics and docking outputs observed in this study needs to be further validated using in vitro and in vivo studies.

hepatitis C virusanti-HCV activityphytochemicalsJatropha tanjorensis
مراجعةمفتوح (مستودع)2026

The Impact of Body Weight on Aspirin’s Antiplatelet Efficacy: A Narrative Review of Conflicting Evidences and Clinical Implications

Advanced Health Science and Technology Journal · مجلد 2 (1) · 21-26

Abstract Aspirin is one of the oldest and most used anti-platelet medications for the prevention of cardiovascular diseases. There has been conflicting research recently about how body weight affects the antiplatelet effectiveness of aspirin. The purpose of this narrative review was to examine the recent research on the connection between aspirin responsiveness, platelet function, and obesity. To find patterns and discrepancies, pertinent research from PubMed, Scopus, and Google Scholar was rigorously examined and compiled. While some studies showed no discernible effect, others highlighted methodological and population-specific variations by reporting decreased aspirin efficacy in people with higher body weight because of increased platelet reactivity, aspirin deactivation, and altered pharmacokinetics, underscoring the need for well-designed, large-scale clinical investigations. The need for carefully planned, extensive clinical studies is highlighted by the fact that the evidence is still equivocal overall. A better understanding of these mechanisms may support the development of personalized antiplatelet strategies, including tailored aspirin dosing in selected subgroups such as obese patients with high thrombotic risk.

aspirinbody weightobesityantiplatelet efficacy
مراجعةمفتوح (مستودع)202538استشهاد· Semantic Scholar

Nutraceutical Potential of Anthocyanins: A Comprehensive Treatise

Food Science & Nutrition · مجلد 13 (5) · e70164-e70164

ABSTRACT Anthocyanins (Anthos; flower and kyanos; blue) are natural coloring compounds from the flavonoids class that include cyanidin, peonidin, delphinidin, malvidin, pelargonidin, and petunidin. Recently, the role of anthocyanins in disease prevention, especially inflammation, diabetes, cancer, neuro‐disorders, hepato‐renal protective, and immuno‐modulation properties has been highlighted. The current review covered the literature on the pharmacokinetics and pharmacological effects of anthocyanins, especially absorption, distribution, metabolism, and excretion (ADME). The discussion on molecular mechanisms underlying their therapeutic effects is the limelight of the article. The GLUT1, GLUT3, SGLT1, SMCT1, and SMCT2 are the main carriers involved in the transportation of anthocyanins in the gastrointestinal tract. The anthocyanins exert their anticancer effects by reducing the expression of IL‐6, IL‐1β, TNF‐β, COX‐2, downregulation of NF‐kB, EZH2, MDR1, Akt , and modulation of P13K/AKT and AMPK/mTOR pathways. The reduction in α‐amylase and α‐glucosidase and improved FFAR1 activity results in antidiabetic effects. The regulation of PGC‐1α/NRF2/TFAM, p‐PI3K/Akt/GSK3β, and Nrf2/HO‐1 prevents neurodegeneration. The anthocyanins impose hepato‐renal protective effects via ameliorating NLRP3 inflammasome, inhibiting MDA, GSSG, iNOS, HO‐1, ICAM‐1, β2‐microglobulin, and MPO activity, and improved SOD, CAT, and GSH activity. Anthocyanins promote beneficial gut microbiota and enhance SCFA production, thus inhibiting pro‐inflammatory markers. The immuno‐modulatory impact of anthocyanins involves the reduction of CRP, P‐selectin, C1q, and C4. Anthocyanins reduce LDL, VLDL, TGs, and TC via improved GBA and upregulation of ATP6 V0C, ZO‐1, and ATG4D expression. The WHO/FAO suggested that 2.5 mg/kg/day of grape‐skin extracts of anthocyanins are safe, and China recommended that 50 mg/day of anthocyanins are safe for consumption. In a nutshell, the multifaceted health benefits of anthocyanins make them promising candidates for disease prevention and therapeutic interventions.

anthocyaninsflavonoidsnutraceuticalsdisease prevention
مقالمفتوح (مستودع)202510استشهاد· Semantic Scholar

Discovery of new thiadiazole-based VEGFR-2 inhibitors: design, synthesis, cytotoxicity, and apoptosis induction

Future Medicinal Chemistry · مجلد 17 (17) · 2145-2162

BACKGROUND: Vascular endothelial growth factor receptor-2 (VEGFR-2) is a validated target in cancer therapy. However, approved inhibitors like sorafenib are often limited by off-target toxicity and resistance. This study aimed to develop novel thiadiazole-based VEGFR-2 inhibitors with improved selectivity and safer profiles. METHODS: A series of 2,3-dihydro-1,3,4-thiadiazole derivatives was rationally designed, synthesized, and structurally characterized. In vitro cytotoxicity was assessed against MCF-7, HepG-2, HCT-116, and normal WI-38 cells. Mechanistic assays included flow cytometry for cell cycle and apoptosis, and ELISA for caspase-3, Bcl-2, and Bax expression. Molecular docking, 200-ns molecular dynamics (MD) simulations, density functional theory (DFT) calculations, and in silico toxicity profiling supported experimental findings. RESULTS: Compound 11a exhibited the most potent and selective activity (IC₅₀: 9.49 µM for MCF-7, 12.89 µM for HepG-2; SI > 3). It induced >70% apoptosis and dual-phase (S and G2/M) cell cycle arrest. VEGFR-2 inhibition (IC₅₀ = 0.055 µM) was comparable to sorafenib. Computational studies confirmed stable binding at VEGFR-2 active sites. CONCLUSION: Compound 11a is a promising thiadiazole-based candidate with notable in vitro potency, selectivity, and mechanistic activity, supporting its potential for further pharmacokinetics/toxicity evaluation and structural refinement as a VEGFR-2-targeted agent.

VEGFR-2 inhibitorsthiadiazole derivativesanticancer drug discoveryapoptosis induction
مقالوصول مفتوح20258استشهاد· Semantic Scholar

New nicotinamide–thiadiazol hybrids as VEGFR-2 inhibitors for breast cancer therapy: design, synthesis and in silico and in vitro evaluation

RSC Advances · مجلد 15 (18) · 14477-14498

mechanistic studies further confirmed the activation of the intrinsic apoptotic pathway, as evidenced by caspase-3 activation (8.2-fold), Bax upregulation (6.9-fold), and Bcl-2 downregulation (3.68-fold). Computational studies, including molecular docking and 200 ns molecular dynamics (MD) simulations, confirmed the stable interaction of 7a with VEGFR-2, showing binding affinities comparable to sorafenib. Further validation through MM-GBSA, ProLIF, PCAT, and FEL analyses reinforced its strong binding capability. Additionally, ADMET predictions suggested favorable pharmacokinetic properties, including good absorption, high plasma protein binding, and non-CYP2D6 inhibition. Moreover, toxicity analysis classified 7a as non-mutagenic and non-carcinogenic, with a lower predicted toxicity than sorafenib. Finally, density functional theory (DFT) calculations highlighted the structural stability and reactivity of 7a, further supporting its potential as a VEGFR-2 inhibitor. These findings suggest that 7a is a promising VEGFR-2 inhibitor with significant anticancer potential, favorable pharmacokinetics, and an improved safety profile. Further preclinical studies and structural modifications are warranted to optimize its therapeutic potential.

VEGFR-2 inhibitorsbreast cancerapoptosiscaspase-3 activation
مراجعةوصول مغلق20257استشهاد· Semantic Scholar

From Plants to Patients: Advancing Cancer Therapy With Bioengineered Exosomes and AI ‐Driven Innovations

Phytotherapy Research · مجلد 39 (10) · 4566-4614

Cancer is a leading global cause of death, with complex pathogenesis and treatment challenges like poor selectivity, toxicity, and drug resistance. Nanotechnology offers transformative solutions, with plant-derived exosomes (EXOs) emerging as promising green nanomaterials for personalized cancer therapy because of their biocompatibility and minimal antigenicity, and eco-friendly production. This review discusses the potential of plant EXOs in cancer treatment, covering isolation methods, advantages over mammalian EXOs (e.g., stability, cost-effectiveness, and evasion of drug resistance mechanisms), and preclinical applications. For instance, ginger EXOs suppress colorectal cancer via cytokine modulation, grapefruit EXOs target brain tumors, and lemon EXOs induce apoptosis in triple-negative breast cancer. Plant EXOs also enhance drug delivery when loaded with chemotherapeutics, nucleic acids, or immunomodulators, improving precision and reducing off-target effects. Despite their promise, challenges remain in scalability, purity, long-term safety for non-oral routes, and clinical translation. Future research must optimize isolation techniques, clarify molecular mechanisms, and validate pharmacokinetics to advance clinical adoption. This review offers a complete examination of plant EXOs, including biogenesis, characterization, engineering strategies, anti-cancer mechanisms (e.g., apoptosis induction, immune modulation), and therapeutic applications. It also addresses hurdles like standardization and regulatory gaps while advocating interdisciplinary collaboration to bridge lab-to-clinic gaps. By harnessing plant EXOs' potential, this work highlights a path toward sustainable, targeted cancer therapies, urging further innovation to overcome existing barriers and realize their full clinical impact.

plant-derived exosomescancer therapygreen nanomaterialsexosome isolation
مقالوصول مغلق20256استشهاد· Semantic Scholar

Development and evaluation of mucoadhesive buccal films for sustained release of glipizide using natural proteins

Drug Development and Industrial Pharmacy · مجلد 51 (8) · 930-942

PURPOSE: To address the challenges of frequent glipizide dosing, including its variable bioa-vailability and gastrointestinal side effects, this study developed and evaluated mucoadhesive buccal films using natural proteins (albumin, gelatin, casein) combined with HPMC E15 to achieve sustained drug delivery. METHODS: Nine formulations (F1-F9) were prepared using solvent casting technique and sys-tematically characterized. Comprehensive evaluations included: (1) drug-polymer compatibil-ity studies (FT-IR, DSC), (2) physicochemical characterization (thickness, weight uniformity, swelling index, moisture content, folding endurance, surface pH), (3) ex-vivo permeation studies through sheep buccal mucosa, and (4) stability assessments to determine film longevi-ty. RESULTS: Compatibility studies utilizing FT-IR and DSC confirmed no significant incompati-bility between glipizide and the excipients. Some of the important physicochemical character-istics recorded for different formulations were surface pH (6.6 - 6.8), folding endurance (72 - 184), moisture content (5.66 - 12.54%), thickness (0.171 - 0.236 mm), weight (0.150 - 0.238 mg), and swelling index (15.8% after 1 hour to 86.6% after 5 hours). Furthermore, neg-ligible variation was observed in these characteristics when stability studies were conducted after 3 months. The ex-vivo permeation studies demonstrated a sustained release of glipizide over 8 hours, with release percentages ranging from 80.94% to 90%. Formulation F6, which achieved an 8-hour release of 89.29%, was identified as optimal. Kinetic analysis revealed zero-order release kinetics for all formulations. CONCLUSION: The developed mucoadhesive buccal films exhibited excellent sustained-release properties, representing a significant improvement over conventional dosage forms. This in-novative delivery system shows strong potential for enhancing diabetes management through improved bioavailability and patient compliance, while minimizing gastrointestinal side effects.

mucoadhesive buccal filmsglipizidesustained drug releasenatural proteins
مقالمفتوح (مستودع)20255استشهاد· Semantic Scholar

Anti-breast cancer potential of thieno-pyrimidine derivatives as VEGFR-2 inhibitors

Future Medicinal Chemistry · مجلد 17 (7) · 803-818

Background Thieno-pyrimidine derivatives have emerged as promising candidates for VEGFR-2 inhibition. This study aimed to design, synthesize, and evaluate novel thieno-pyrimidine derivatives for their anti-cancer potential.Methods A series of thieno-pyrimidine compounds were synthesized and screened for in vitro cytotoxicity against MDA-231 and MCF-7 cell lines. The most active compound, 6b, was further analyzed for VEGFR-2 kinase inhibition, wound healing, apoptosis induction, and cell cycle arrest. Molecular docking, 200 ns molecular dynamics simulations, MM-GBSA, ProLIF PCAT, and FEL analyses were conducted to assess binding stability. DFT calculations evaluated electronic properties, while in silico ADMET profiling predicted pharmacokinetics and toxicity.Results Compound 6b exhibited potent cytotoxicity with IC50 values of 5.91 µM (MDA-231) and 7.16 µM (MCF-7). It demonstrated VEGFR-2 inhibition is comparable to sorafenib (IC50: 53.63 ± 3.14 nM). Wound healing assays showed significant inhibition of MDA-231 migration. Flow cytometry confirmed apoptosis induction (57.20% early apoptosis) and G1 phase arrest. Gene expression analysis revealed upregulation of pro-apoptotic markers and downregulation of Bcl-2. Computational studies confirmed stable VEGFR-2 binding, and ADMET predictions indicated a favorable safety profile.Conclusion Compound 6b exhibits strong VEGFR-2 inhibition, potent anti-cancer effects, and a favorable toxicity profile, highlighting its potential for further therapeutic development.

VEGFR-2 inhibitorsbreast canceranticancer agentscytotoxicity
مقالوصول مفتوح202411استشهاد

Preparation and Characterization of Novel Polyelectrolyte Liposomes Using Chitosan Succinate Layered over Chitosomes: A Potential Strategy for Colon Cancer Treatment

Biomedicines · مجلد 12 (1) · 126-126

Chitosan succinate is distinguished by its ability to shield the loaded drug from the acidic environment, localize and keep the drug at the colon site, and release the drug over an extended time at basic pH. The current study attempts to develop polyelectrolyte liposomes (PEL), using chitosan and chitosan succinate (CSSC), as a carrier for liposomal-assisted colon target delivery of 5 fluorouracil (5FU). The central composite design was used to obtain an optimized formulation of 5FU-chitosomes. The chitosan-coated liposomes (chitosomes) were prepared by thin lipid film hydration technique. After that, the optimized formulation was coated with CSSC, which has several carboxylic (COOH) groups that produce an anionic charge that interacts with the cation NH2 in chitosan. The prepared 5FU-chitosomes formulations were evaluated for entrapment efficiency % (EE%), particle size, and in vitro drug release. The optimized 5FU-chitosomes formulation was examined for particle size, zeta potential, in vitro release, and mucoadhesive properties in comparison with the equivalent 5FU-liposomes and 5FU-PEL. The prepared 5FU-chitosomes exhibited high EE%, small particle size, low polydispersity index, and prolonged drug release. PEL significantly limited the drug release at acidic pH due to the deprotonation of carboxylate ions in CSSC, which resulted in strong repulsive forces, significant swelling, and prolonged drug release. According to a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay, PEL treatment significantly decreased the viability of HT-29 cells. When compared to 5FU-liposome and 5FU-chitosome, the in vivo pharmacokinetics characteristics of 5FU-PEL significantly (p < 0.05) improved. The findings show that PEL enhances 5FU permeability, which permits high drug concentrations to enter cells and inhibits the growth of colon cancer cells. Based on the current research, PEL may be used as a liposomal-assisted colon-specific delivery.

chitosan succinatechitosomes5-fluorouracilcolon-targeted drug delivery
مقالمفتوح (مستودع)2024

Synthesis and Characterization of Mesoporous SBA-15 as Carriers to Improve the Rutin Dissolution Rate

Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic Agents · مجلد 38 (7)

Background: Due to its low water solubility, Rutin, a crystalline medication used to treat a variety of conditions, has a limited rate of dissolution when given in gastrointestinal fluids. The present study planned to formulate and characterize Rutin using mesoporous silica material (SBA-15) as well as to determine the in-vitro dissolution properties. Methods: Rutin was formulated using mesoporous silica material such as SBA-15. Particle size distribution analysis, fourier transform-infrared (FT-IR) spectroscopy, scanning electron microscopy, and X-ray diffraction were used to characterize the compound in the complex. Rutins solubility and in-vitro release characteristics were assessed. Furthermore, the dissolution data (DD) Solver Excel add-in software was used to evaluate several mathematical models to interpret the Rutin dissolution kinetics from the mesoporous materials. Results: Differential scanning calorimetry was used to confirm Rutins amorphous state, which resulted in a significantly higher rate of dissolution than pure crystalline Rutin. The release of the drug from the Rutin/SBA-15 complex was well-simulated by the Weibull model. Notably, the SBA-15 carrier-mediated complex of Rutin exhibited the highest drug loading and dissolution rate, showing promising potential for enhancing Rutin bioavailability. Conclusion: The findings suggested that Rutin/SBA-15 could be easily incorporated into conventional oral pharmaceutical dosage forms such as capsules and therefore can be utilized for treating ailments such as allergies, inflammation, tumors, infections, protozoal diseases, and spasms. To assess the Rutin/SBA-15 complexs in-vivo pharmacokinetic performance and appropriateness for a range of pharmacological actions, more investigation is required.

rutinSBA-15mesoporous silicadrug dissolution rate
مقالوصول مفتوح202334استشهاد· Semantic Scholar

Anti-Tumor Activity of Orally Administered Gefitinib-Loaded Nanosized Cubosomes against Colon Cancer

Pharmaceutics · مجلد 15 (2) · 680-680

Gefitinib (GFT) is a tyrosine kinase inhibitor drug used as a first-line treatment for patients with advanced or metastatic non-small cell lung, colon, and breast cancer. GFT exhibits low solubility and hence low oral bioavailability, which restricts its clinical application. One of the most important trends in overcoming such problems is the use of a vesicular system. Cubosomes are considered one of the most important vesicular systems used to improve solubility and oral bioavailability. In this study, GFT cubosomal nanoparticles (GFT-CNPs) were prepared by the emulsification method. The selected formulation variables were analyzed and optimized by full factorial design and response surface methodology. Drug entrapment efficiency (EE%), transmission electron microscopy, particle size, polydispersity index, in vitro release and its kinetics, and the effect of storage studies were estimated. The chosen GFT-CNPs were subjected to further investigations as gene expression levels of tissue inhibitors of metalloproteinases-1 (TIMP-1) and matrix metalloproteinases-7 (MMP-7), colon biomarkers, and histopathological examination of colon tissues. The prepared GFT-CNPs were semi-cubic in shape, with high EE%, smaller vesicle size, and higher zeta potential values. The in vivo data showed a significant decrease in the serum level of embryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), and gene expression level of TIMP-1 and MMP-7. Histopathological examination showed enhancement in cancer tissue and highly decreased focal infiltration in the lamina propria after treatment with GFT-CNPs.

gefitinibcubosomescolon canceroral bioavailability
مراجعةوصول مفتوح202326استشهاد· Semantic Scholar

Resveratrol-Laden Nano-Systems in the Cancer Environment: Views and Reviews

Cancers · مجلد 15 (18) · 4499-4499

The genesis of cancer is a precisely organized process in which normal cells undergo genetic alterations that cause the cells to multiply abnormally, colonize, and metastasize to other organs such as the liver, lungs, colon, and brain. Potential drugs that could modify these carcinogenic pathways are the ones that will be used in clinical trials as anti-cancer drugs. Resveratrol (RES) is a polyphenolic natural antitoxin that has been utilized for the treatment of several diseases, owing to its ability to scavenge free radicals, control the expression and activity of antioxidant enzymes, and have effects on inflammation, cancer, aging, diabetes, and cardioprotection. Although RES has a variety of pharmacological uses and shows promising applications in natural medicine, its unpredictable pharmacokinetics compromise its therapeutic efficacy and prevent its use in clinical settings. RES has been encapsulated into various nanocarriers, such as liposomes, polymeric nanoparticles, lipidic nanocarriers, and inorganic nanoparticles, to address these issues. These nanocarriers can modulate drug release, increase bioavailability, and reach therapeutically relevant plasma concentrations. Studies on resveratrol-rich nano-formulations in various cancer types are compiled in the current article. Studies relating to enhanced drug stability, increased therapeutic potential in terms of pharmacokinetics and pharmacodynamics, and reduced toxicity to cells and tissues are the main topics of this research. To keep the readers informed about the current state of resveratrol nano-formulations from an industrial perspective, some recent and significant patent literature has also been provided. Here, the prospects for nano-formulations are briefly discussed, along with machine learning and pharmacometrics methods for resolving resveratrol's pharmacokinetic concerns.

resveratrolnanocarriersnanoformulationscancer therapy
مقالوصول مفتوح202314استشهاد· Semantic Scholar

Development of a New Class of Monoamine Oxidase-B Inhibitors by Fine-Tuning the Halogens on the Acylhydrazones

ACS Omega · مجلد 8 (50) · 47606-47615

High Resolution Image Download MS PowerPoint Slide A total of 14 acyl hydrazine derivatives ( ACH1–ACH14 ) were developed and examined for their ability to block monoamine oxidase (MAO). Thirteen analogues showed stronger inhibition potency against MAO-B than MAO-A. With a half-maximum inhibitory concentration of 0.14 μM, ACH10 demonstrated the strongest inhibitory activity against MAO-B, followed by ACH14, ACH13, ACH8, and ACH3 (IC 50 = 0.15, 0.18, 0.20, and 0.22 μM, respectively). Structure–activity relationships suggested that the inhibition effect on MAO-B resulted from the combination of halogen substituents of the A- and/or B-rings. This series concluded that when –F was substituted to the B-ring, MAO-B inhibitory activities were high, except for ACH6 . In the inhibition kinetics study, the compounds ACH10 and ACH14 were identified as competitive inhibitors, with K i values of 0.097 ± 0.0021 and 0.10 ± 0.038 μM, respectively. In a reversibility experiment using the dialysis methods, ACH10 and ACH14 showed effective recoveries of MAO-B inhibition as much as lazabemide, a reversible reference. These experiments proposed that ACH10 and ACH14 were efficient, reversible competitive MAO-B inhibitors. In addition, the lead molecules showed good blood–brain barrier permeation with the PAMPA method. The molecular docking and molecular dynamics simulation study confirmed that the hit compound ACH10 can form a stable protein–ligand complex by forming a hydrogen bond with the NH atom in the hydrazide group of the compound.

monoamine oxidase B inhibitorsacylhydrazoneshalogen substituentsstructure-activity relationship